文献速递贫血与红细胞疾病血栓与止血

遗传性出血性毛细血管扩张症的医疗资源利用与费用特征

Characterizing the Healthcare Utilization and Costs of Hereditary Hemorrhagic Telangiectasia.
PubMed 文献 · Am J Hematol · 2025-07-02

本研究利用美国Komodo医疗索赔数据库,纳入2022年和2023年诊断为遗传性出血性毛细血管扩张症(HHT)的患者(分别为24407例和23524例),量化其住院、门诊和药房费用。

要点

  • HHT患者年均费用约19000美元,合并贫血者约27000美元,接受血液学支持者约40000美元。
  • 贫血患者约占HHT患者的60%,但占直接医疗费用的约80%。
  • 在多数主要费用驱动因素中,贫血及贫血治疗占费用的75%-100%。

核心结论

  • HHT的年均费用与其他罕见、资源密集型严重疾病(包括镰状细胞病、肌营养不良和囊性纤维化)相当或更高。

研究设计与样本

  • 利用Komodo医疗索赔数据库构建美国HHT患者大样本,包括贫血亚组和接受血液学支持(铁输注和/或红细胞输注)亚组。
  • 量化2022年和2023年每患者每年平均费用及总人群住院、门诊和药房费用。

主要发现

  • 全部HHT患者(2022年n=24407;2023年n=23524)的年均每患者费用约为19000美元。
  • 贫血患者(2022年n=13856;2023年n=13192)的年均每患者费用约为27000美元。
  • 接受血液学支持患者(2022年n=6191;2023年n=5818)的年均每患者费用约为40000美元。
  • 贫血患者约占HHT患者的60%,但占直接医疗费用的约80%;在多数主要住院、门诊和药房费用驱动因素中,贫血及贫血治疗占费用的75%-100%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hereditary hemorrhagic telangiectasia (HHT) is the second-most common inherited bleeding disorder worldwide, afflicting one in 4000-5000 people, and is the most morbid inherited bleeding disorder of women. HHT causes recurrent severe epistaxis, chronic gastrointestinal bleeding, heavy menstrual bleeding, and arteriovenous malformations in the lung, liver, and brain that cause serious bleeding and nonbleeding complications. There are no approved treatments worldwide, and the direct medical costs of HHT have not been well-characterized. We utilized the Komodo Healthcare Map claims database to create a large sample of US patients diagnosed with HHT, including a subgroup with anemia and a subgroup receiving hematologic support (iron infusions and/or red cell transfusions). We quantified mean per patient per year (PPPY) and total population inpatient, outpatient, and pharmacy costs in 2022 and 2023. The mean PPPY costs for all HHT patients (n = 24 407; n = 23 524), those with anemia (n = 13 856; n = 13 192) and those receiving hematologic support (n = 6191; n = 5818) were approximately $19 000, $27 000, and $40 000, respectively, across years, representing > $450 000 000 in annual healthcare costs in the sample. The leading cost drivers were related to treatment for bleeding and its consequences. While accounting for nearly 60% of HHT patients, those with anemia accounted for ~80% of direct medical costs. Across the majority of leading inpatient, outpatient, and pharmacy cost drivers, patients with anemia and anemia treatment accounted for 75%-100% of cost. The PPPY costs of HHT are comparable to, or exceed, those of other rare, resource-intensive serious diseases, including sickle cell disease, muscular dystrophy, and cystic fibrosis.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Al-Samkari H, Mayne TJ, Troutt M, et al. Characterizing the Healthcare Utilization and Costs of Hereditary Hemorrhagic Telangiectasia. Am J Hematol. 2025. PMID: 40600700. doi:10.1002/ajh.27756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。